Advertisement

Topics

Five Prime’s Shakeup Cuts Staff 20%, Keeps Focus on Clinical Programs

18:45 EST 15 Jan 2019 | Xconomy

Five Prime Therapeutics is cutting its headcount by 20 percent, part of a cash-saving effort the company is making to focus on the cancer drugs it has already advanced into clinical trials. South San Francisco, CA-based Five Prime (NASDAQ: FPRX) said Tuesday that the corporate restructuring will reduce operating expenses by $10 million in 2019 […]

Original Article: Five Prime’s Shakeup Cuts Staff 20%, Keeps Focus on Clinical Programs

NEXT ARTICLE

More From BioPortfolio on "Five Prime’s Shakeup Cuts Staff 20%, Keeps Focus on Clinical Programs"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...